GeneDx Holdings (WGS) Change in Accured Expenses (2020 - 2026)

GeneDx Holdings (WGS) has reported Change in Accured Expenses for 7 consecutive years, with $602000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Accured Expenses rose 116.61% year-over-year to $602000.0 in Q2 2026; TTM through Jun 2026 was -$7.7 million, a 212.35% decrease from a year earlier, with the FY2025 full-year figure at $12.1 million, up 158.96% from the prior year.
• Change in Accured Expenses was $602000.0 for Q2 2026 at GeneDx Holdings, up from -$13.2 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $42.3 million in Q2 2022 and troughed at -$14.5 million in Q3 2023.
• A 5-year average of -$2.0 million and a median of -$5.4 million in 2024 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses slumped 256.79% in 2023 and soared 328.69% in 2025, its largest moves.
• Over 5 years, Change in Accured Expenses stood at $5.9 million in 2022, then tumbled by 256.79% to -$9.3 million in 2023, then tumbled by 37.42% to -$12.7 million in 2024, then soared by 154.38% to $6.9 million in 2025, then sank by 91.29% to $602000.0 in 2026.
• The last three Change in Accured Expenses figures came in at $602000.0 (Q2 2026), -$13.2 million (Q1 2026), and $6.9 million (Q4 2025), per Business Quant data.